A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
- Conditions
- Obesity
- Registration Number
- NCT05567796
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 3400
Inclusion Criteria:<br><br> - Male or female<br><br> - Age above or equal to 18 years at the time of signing informed consent<br><br> - Body mass index (BMI) greater than or equal to 30.0 kilograms per square meter<br> (kg/m^2) or b) BMI greater than or equal to 27.0 kg/m^2 with the presence of at<br> least one weight-related comorbidity including, but not limited to hypertension,<br> dyslipidaemia, obstructive sleep apnoea or cardiovascular disease<br><br>Exclusion Criteria:<br><br> - Glycaemia related: a) Glycated Haemoglobin (HbA1c) greater than or equal to 6.5<br> percent (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at<br> screening b) History of type 1 or type 2 diabetes mellitus
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weight;CagriSema 2.4 mg/2.4 mg versus placebo: Achievement of greater than or equal to (>=) 5% weight reduction
- Secondary Outcome Measures
Name Time Method